الإحصائيات الأساسية
| CIK | 1059784 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Generex Biotechnology Corp
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: July 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q |
|
| July 23, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| July 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 21, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-25169 Generex Biotechnology Cor |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: April 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10- |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissio |
|
| April 27, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissio |
|
| March 17, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-25169 Generex Biotechnology C |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commiss |
|
| February 2, 2021 |
Other Events, Financial Statements and Exhibits 8-K 1 gnbt020221form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisd |
|
| February 2, 2021 |
GENEREX BIOTECHNOLOGY CORPORATION February 1, 2020 GENEREX BIOTECHNOLOGY CORPORATION February 1, 2020 Securities Transfer Corporation 2901 N. |
|
| January 8, 2021 |
Performance Guarantee Fee January 6, 2021 Performance Guarantee Fee January 6, 2021 When preform the contract number: YF202011-A signed on November 13, 2020, the payment was delayed due to more complicated procedures than the originally planned. |
|
| January 8, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissi |
|
| December 21, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-25169 Generex Biotechnology C |
|
| December 17, 2020 |
Dear Joseph, We know it is time for us to make payment. Since the procedure for establishing a biological company is longer than we originally expected, we have to request an extension. 1, we already prepared fund in RMB 2, Chinese authority already accepted our company registration application, we expect to get approval this week. 3, after getting registration documents, we can open a bank accoun |
|
| December 17, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Comm |
|
| December 17, 2020 |
GENEREX BIOTECHNOLOGY CORPORATION NUGENEREX IMMUNO-ONC0L0GY, INC. 10102 USA Today Way Miramar, FL 33025 December 15, 2020 Via email [email protected] The Ii-Key Innovative COVID-19 Vaccine Development Agreement with China Dear Maggie Wang: Re: Extension for $5 Million Payment to Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Inc. We make reference to your written request for an ex |
|
| December 17, 2020 |
GENEREX BIOTECHNOLOGY CORPORATION NUGENEREX IMMUNO-ONC0L0GY, INC. 10102 USA Today Way Miramar, FL 33025 December 15, 2020 Via email [email protected] The Ii-Key Innovative COVID-19 Vaccine Development Agreement with China Dear Maggie Wang: Re: Extension for $5 Million Payment to Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Inc. We make reference to your written request for an ex |
|
| December 17, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| December 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ¨Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: October 31, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10 |
|
| November 25, 2020 |
Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand • Memorandum of Understanding (MOU) signed by both parties • Negotiating final contract terms • Upfront payment on closing • Licensing fees, expenses, and price per dose to be determined • Bintai Kinden Corporation Berhad (www. |
|
| November 25, 2020 |
Other Events, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| November 25, 2020 |
DATED THIS 21st DAY OF November 2020 BETWEEN BINTAI HEALTHCARE SDN. BHD. (Company Registration No. 1384306-P) AND GENEREX BIOTECHNOLOGY CORPORATION & NUGENEREX IMMUNO-ONCOLOGY, INC ********************************************************************** MEMORANDUM OF UNDERSTANDING ********************************************************************* 1 MEMORANDUM OF UNDERSTANDING BETWEEN BINTAI HEALT |
|
| November 19, 2020 |
The Ii-key innovative flu vaccine development agreement Contract No.: YF202011-B Contract Date: 13th-Nov-2020 The Ii-key innovative flu vaccine development agreement Parties: Party A: Project initiator Beijing Youfeng International Consulting Co., Ltd 1-806 Huirunyuan Jingtong Expy, Shilipu, Chaoyang, Beijing, China And Party B: Project technology investor NuGenerex Immuno-Oncology Inc.(a subsidiary of Generex) 10102 USA Today Way SUITE 200, Miramar, F |
|
| November 19, 2020 |
Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine • $2. |
|
| November 19, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| November 18, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| November 18, 2020 |
CHAPTER 1 SCOPE OF THE TECHNOLOGY COLLABORATION Contract No.: YF202011-A Contract Date: 13th-Nov-2020 The Ii-key innovative vaccine development agreement Parties: Party A: Project initiator Beijing Youfeng International Consulting Co., Ltd 1-806 Huirunyuan Jingtong Expy, Shilipu, Chaoyang, Beijing, China And Party B: Project technology investor Generex Biotechnology Corporation NuGenerex Immuno-Oncology Inc. (a subsidiary of Generex) 10102 USA |
|
| November 18, 2020 |
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform • $50 million licensing deal for the Ii-Key platform to develop vaccines for infectious diseases and cancer • Deal includes first contract for Ii-Key- SARS-CoV-2 vaccine against COVID-19 in China with a $5 million upfront licensing fee, 100% funding for manufacturing, developme |
|
| November 13, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: July 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-29169 Generex Biotechnology Corporation |
|
| November 13, 2020 |
Exhibit 21 Following is a list of the Company's subsidiaries, each of which, unless otherwise indicated, is wholly owned by the Company either directly or through another subsidiary. |
|
| November 5, 2020 |
Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co. |
|
| November 5, 2020 |
Framework Agreement on Cooperative Development of Coronavirus Peptide Vaccine Contract Date: 26th-Oct-2020 Framework Agreement on Cooperative Development of Coronavirus Peptide Vaccine Party A: Beijing Youfeng International Consulting Co. |
|
| November 5, 2020 |
Other Events, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commiss |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: July 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q |
|
| October 9, 2020 |
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets • Bintai Kinden Corporation Berhad (www. |
|
| October 9, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissi |
|
| October 9, 2020 |
CONFIDENTIAL DATED THIS DAY OF 05 OCT 2020 BETWEEN GENEREX BIOTECHNOLOGY CORPORATION ("GENEREX") AND NUGENEREX IMMUNO-ONCOLOGY, INC. |
|
| September 25, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commi |
|
| September 25, 2020 |
REMOTE MONITORING SERVICES AGREEMENT REMOTE MONITORING SERVICES AGREEMENT This Remote Monitoring Services Agreement (“Agreement”) is made by and between NuGenHealth, LLC an Arizona Limited Liability Company, with an address of 11209 N. |
|
| September 25, 2020 |
Exhibit 99.2 Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) Services • NuGenHealth Software as a Service (SaaS) platform launch • PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population MIRAMAR, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) - |
|
| September 24, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commi |
|
| September 24, 2020 |
DATED THIS DAY OF 2020 BETWEEN GENEREX BIOTECHNOLOGY CORPORATION AND NUGENEREX IMMUNO-ONCOLOGY, INC. |
|
| September 24, 2020 |
ANNEXURE 1 FINANCIAL CONSIDERATION ( sums stipulated herein are for reference purposes only) MEMORANDUM OF UNDERSTANDING BETWEEN BINTAI KINDEN CORPORATION BERHAD !Company Registration No. |
|
| September 24, 2020 |
Generex Biotechnology Corporation September 18, 2020 09:00 ET Source: Generex Biotechnology Corporation September 18, 2020 09:00 ET Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia • Bintai Kinden Corporation Berhad (www. |
|
| September 21, 2020 |
The date of this prospectus is September 14, 2020 148,639,455 Shares of Common Stock This prospectus relates to the offer and sale of up to 148,639,455 shares of common stock of Generex Biotechnology Corporation, by the selling stockholders. |
|
| September 18, 2020 |
The date of this prospectus is __ , 2020 23,878,986 Shares of Common Stock This prospectus relates to the offer and sale of up to 23,878,986 shares of common stock of Generex Biotechnology Corporation, by the selling stockholders. |
|
| September 14, 2020 |
Certificate of Designation of Series A Preferred Stock GENEREX BIOTECHNOLOGY CORPORATION CERTIFICATE OF DESIGNATIONS, RIGHTS AND PREFERENCES OF 13% SERIES A CUMULATIVE REDEEMABLE PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the Delaware General Corporation Law Generex Biotechnology Corp. |
|
| September 14, 2020 |
As filed with the Securities and Exchange Commission on September 14, 2020 Registration No. |
|
| September 11, 2020 |
GENEROX BIOTECHNOLOGY CORPORATION 10102 USA Today Way Miramar, FL 33025 September 11, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 11, 2020 |
GENEROX BIOTECHNOLOGY CORPORATION 10102 USA Today Way Miramar, FL 33025 September 11, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 9, 2020 |
September 9, 2020 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| September 9, 2020 |
As filed with the Securities and Exchange Commission on September 9, 2020 Registration No. |
|
| September 3, 2020 |
THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE. |
|
| September 3, 2020 |
September 3, 2020 Generex Biotechnology Corporation 10102 USA Today Way Miramar, FL 33025 Re: Registration Statement on Form S-1 (File No. |
|
| September 3, 2020 |
As filed with the Securities and Exchange Commission on September 3, 2020 Registration No. |
|
| September 3, 2020 |
Exhibit 23.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the use in this Registration Statement on Form S-1 Amendment No. 2 (File No. 333-236481) of our report dated November 12, 2019, related to the consolidated financial statements of Generex Biotechnology Corporation and Subsidiaries as of July 31, 2019 and for the fiscal year then ended, which appears in this |
|
| September 3, 2020 |
THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE. |
|
| September 3, 2020 |
CORRESP 11 filename11.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in this Registration Statement on Form S-1/A (Amendment No. 2) dated September 3, 2020 of our report dated October 26, 2018 relating to the audited consolidated financial statements of Generex Biotechnology Corporation and subsidiaries (which report expresses an unqualified opinion and i |
|
| September 3, 2020 |
As filed with the Securities and Exchange Commission on September 3, 2020 Registration No. |
|
| September 3, 2020 |
September 3, 2020 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| September 3, 2020 |
EX-10.35 2 ex1035.htm EXHIBIT 10.35 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its a |
|
| September 3, 2020 |
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). |
|
| September 3, 2020 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the "Buyer"). |
|
| September 3, 2020 |
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). |
|
| August 31, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissi |
|
| August 31, 2020 |
Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday, August 26th, 2020 at 9:30 AM EasternPress Release | 08/26/2020 • The NuGenHealth Software as a Service (SaaS) System • Remote Patient Monitoring (RPM) • Chronic Care Management (CCM) The access information for the investor conference call remains as follows: Direct Toll / International – 1-(866) 831-8711 Domestic US/Canada - 1-(203) 518-9883 Program Title: Generex Biotechnology Conference Call Conference ID – 89636 MIRAMAR, Fla. |
|
| August 31, 2020 |
Operating Agreement Of NuGenHealth, LLC (An Arizona Limited Liability Company) Operating Agreement ofNuGenHealth, LLC (the "Company" or "NuGenHealth"), dated as of August 2020 by and between Worldwide Digitech, LLC (WWDT) a Florida limited liability company and NuGenerex Health, LLC, ("NuGenerex Health, LLC" an Arizona LLC and subsidiary of Generex Biotechnology Corporation). |
|
| August 21, 2020 |
Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia - Bintai Kinden Corporation Berhad (www. |
|
| August 21, 2020 |
EX-99.2 3 ex992.htm EXHIBIT 99.1 Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia - Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region - |
|
| August 21, 2020 |
Other Events, Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commis |
|
| August 21, 2020 |
ANNEXURE 1 FINANCIAL CONSIDERATION ( sums stipulated herein are for reference purposes only) MEMORANDUM OF UNDERSTANDING BETWEEN BINTAI KINDEN CORPORATION BERHAD !Company Registration No. |
|
| August 21, 2020 |
ANNEXURE 1 FINANCIAL CONSIDERATION ( sums stipulated herein are for reference purposes only) MEMORANDUM OF UNDERSTANDING BETWEEN BINTAI KINDEN CORPORATION BERHAD !Company Registration No. |
|
| August 21, 2020 |
Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissi |
|
| August 20, 2020 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on August 20, 2020 Registration No. |
|
| August 11, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| August 11, 2020 |
EXECUTION COPY NOTE SETTLEMENT AGREEMENT This Note Settlement Agreement (this “Agreement”) is entered into as of July 31, 2020 (the “Effective Date”) by and between Iliad Research and Trading, L. |
|
| August 7, 2020 |
Execution Version SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of August 4, 2020, by and among Generex Biotechnology Corporation, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, Florida 33025 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers"). |
|
| August 7, 2020 |
EX-4.5 6 ex45.htm EXHIBIT 4.5 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of August 4, 2020, by and among Generex Biotechnology Corporation, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, Florida 33025 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (each, a "Buyer" and collectively |
|
| August 7, 2020 |
FORM OF SERIES B WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissio |
|
| August 7, 2020 |
EX-4.1 2 ex41.htm EXHIBIT 4.1 FORM OF SERIES A WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A |
|
| August 7, 2020 |
FORM OF SERIES D WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| August 7, 2020 |
FORM OF SERIES C WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| July 27, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| July 27, 2020 |
EX-99.2 3 ex992.htm EXHIBIT 99.2 Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key- SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020 - FDA to provide written response with guidance on the proposed comprehensive clinical development program for Ii-Key- SARS-CoV-2 prophylactic peptide vaccine against COVID-19 MIRAMAR, |
|
| July 27, 2020 |
Meeting Confirmation Date: July 24, 2020 Meeting ID #: CRMTS# 12733 Submission type & #: Pre-IND, PS005752 Requester: Marci Aderive PPD Development, LLP (Agent for NuGenerex Immuno-Oncology) Meeting type: Type B Meeting category: Pre-IND Product: Synthetic Ii-Key-SARS-CoV-2 prophylactic multivalent peptide vaccine alone and in combination with 3M's imidazoquinoline adjuvant (3M-052) Indication: Prophylactic immunization against COVID-19 in healthy adults Meeting format: Written Responses We acknowledge receipt of your meeting package submitted on July 17, 2020. |
|
| July 17, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| July 17, 2020 |
ILIAD RESEARCH AND TRADING, L.P., a Utah limited partnership, The Order of the Court is stated below: Dated: July 13, 2020 03:58:04 PM /s/ ROYAL I HANSEN District Court Judge Jeremy C. |
|
| July 17, 2020 |
ILIAD RESEARCH AND TRADING, L.P., a Utah limited partnership, The Order of the Court is stated below: Dated: July 14, 2020 10:35:14 AM /s/ ROYAL I HANSEN District Court Judge ROBERT T. |
|
| July 14, 2020 |
July 14, 2020 BY EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| July 14, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 3) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: July 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-25169 Generex Biotec |
|
| July 14, 2020 |
Exhibit 31.1 CERTIFICATIONS I, Joseph Moscato, certify that: 1. I have reviewed this annual report on Form 10-K/A of Generex Biotechnology Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| July 14, 2020 |
Exhibit 31.2 CERTIFICATIONS I, Mark Corrao, certify that: 1. I have reviewed this annual report on Form 10-K/A of Generex Biotechnology Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 29, 2020 |
10-K/A 1 gnbt073119form10ka.htm FORM 10-K/A United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: July 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to |
|
| June 23, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 23, 2020 |
April 15, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the li-Key-SARS-CoV-2 p |
|
| June 22, 2020 |
EX-10.39 14 ex1039.htm EXHIBIT 10.39 May 26, 2020 Via Electronic Mail Generex Biotechnology Corporation 10102 USA Today Way Miramar, FL 33025 Attention: Joseph Moscato, Chairman & CEO Re: Retainer for Legal Representation Dear Mr. Moscato: Reference is made to our letters dated December 5, 2019 (the “December 2019 Retainer”), pursuant to which you engaged Carmel, Milazzo & Feil LLP (the “Firm”) to |
|
| June 22, 2020 |
THE ISSUE PRICE OF THIS NOTE IS $50,000.00 EX-10.37 12 ex1037.htm EXHIBIT 10.37 THE ISSUE PRICE OF THIS NOTE IS $50,000.00 Principal Amount: $50,000.00 Issue Date: April 9, 2020 Purchase Price: $50,000.00 PROMISSORY NOTE FOR VALUE RECEIVED, GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation with a business address located at 10102 USA Today Way, Miramar, Florida, 33025 ("Debtor") promises to pay to the order of Michael Caridi (“Lend |
|
| June 22, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 22, 2020 |
April 17, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV-2 p |
|
| June 22, 2020 |
THE ISSUE PRICE OF THIS NOTE IS $100,000.00 Principal Amount: $100,000.00 Issue Date: May 4, 2020 Purchase Price: $100,000.00 PROMISSORY NOTE FOR VALUE RECEIVED, GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation with a business address located at 10102 USA Today Way, Miramar, Florida, 33025 ("Debtor") promises to pay to the order of Michael Caridi (“Lender") the sum of ONE HUNDRED THOUSAND |
|
| June 22, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 0-25169 Generex Biotechnology Corpo |
|
| June 19, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 19, 2020 |
GENEREX BIOTECHNOLOGY CORPORATION June 19, 2020 Securities and Exchange Commission 100 F Street, N. |
|
| June 19, 2020 |
April 27, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV-2 p |
|
| June 18, 2020 |
April 15, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the li-Key-SARS-CoV-2 p |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissi |
|
| June 17, 2020 |
U.S. Department of Health and Human Services U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV-2 peptide vaccine |
|
| June 17, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 16, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 16, 2020 |
April 16, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is my understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the li-Key-SARS-CoV-2 pe |
|
| June 15, 2020 |
As filed with the Securities and Exchange Commission on June 15, 2020 Registration No. |
|
| June 15, 2020 |
As filed with the Securities and Exchange Commission on June 15, 2020 Registration No. |
|
| June 15, 2020 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in this Registration Statement on Form S-1 Amendment No. |
|
| June 15, 2020 |
S-1/A 1 gnbt061220forms1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on June 15, 2020 Registration No. 333-235461 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/ A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 2834 |
|
| June 15, 2020 |
Exhibit 23.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the use in this Registration Statement on Form S-1 Amendment No. 1 (File No. 333-236481) of our report dated November 12, 2019, related to the consolidated financial statements of Generex Biotechnology Corporation and Subsidiaries as of July 31, 2019 and for the fiscal year then ended, which appears in this |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: April 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q |
|
| June 15, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 gnbt061520form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other juri |
|
| June 15, 2020 |
Generex Biotechnology Corporation 10102 USA Today Way Miramar, FL 33025 June 15, 2020 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Re: Generex Biotechnology Corporation Registration Statement on Form S-1 Filed February 18, 2020 File No. |
|
| June 15, 2020 |
As filed with the Securities and Exchange Commission on June 15, 2020 Registration No. |
|
| June 15, 2020 |
As filed with the Securities and Exchange Commission on June 15, 2020 Registration No. |
|
| June 15, 2020 |
U.S. Department of Health and Human Services U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is my understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV2 peptide vaccine wi |
|
| June 12, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 12, 2020 |
April 15, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV-2 p |
|
| June 11, 2020 |
April 24, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV-2 p |
|
| June 11, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 10, 2020 |
3M Health Care Business Group 3M Center, 275-4W-02 St. Paul, MN 55144-100 United States 3M April 28, 2020 U.S. Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA): It is our understanding that Generex Biotechnology is working |
|
| June 10, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: July 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-25169 Generex Biotec |
|
| June 10, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 8, 2020 |
Appendix A Statement of Work (incorporated by reference to 8-K filed June 8, 2020) APPENDIX A- Statement of Work This Statement of Work #1 (“SOW”), dated and effective May 18, 2020, submitted in connection with the Laboratory Services Agreement by and between Cellular Technology Limited (“CTL”) and Generex Biotechnology Corporation, a public company organized under the laws of Delaware , with its principal place of business located at 10102 USA Today Way, Miramar, FL 33025 (“Company”) (“Company”) dated May 15, 2020 (“Agreement”), is hereby agreed to by the Parties. |
|
| June 8, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 GENEREX BIOTECHNOLOGY CORPORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| June 8, 2020 |
Laboratory Services Agreement (incorporated by reference to 8-K filed June 8, 2020) Laboratory Services AGreement This Laboratory Services Agreement (“Agreement”) is made and entered into as of May 15, 2020 (“Effective Date”) by and between Cellular Technology Limited, an Ohio limited liability company organized under the laws of Ohio, with its principal place of business located at 20521 Chagrin Boulevard, Shaker Heights, Ohio 44122 (“CTL”), and Generex Biotechnology Corporation, a public company organized under the laws of Delaware , with its principal place of business located at 10102 USA Today Way, Miramar, FL 33025 (“Company”). |
|
| March 20, 2020 |
GNBT / Generex Biotechnology Corp. 10-Q - Quarterly Report - FORM 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 0-25169 Generex Biotechnology Cor |
|
| March 17, 2020 |
MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”) is made effective as of March 3, 2020 (“Effective Date”), by and between Generex Biotechnology Corporation, a Delaware corporation (“Generex”), with offices at 10102 USA Today Way, Miramar, FL 33025, and EpiVax Inc. |
|
| March 17, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Marsh 3, 2020 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission |
|
| March 17, 2020 |
EX-99.1 3 ex991.htm EXHIBIT 99.1 Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic MIRAMAR, Fla., March 04, 2020 (GLOBE NEWSWIRE) - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a contract with EpiVax (https://epivax.com/) to use |
|
| March 16, 2020 |
GNBT / Generex Biotechnology Corp. NT 10-Q - - FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: January 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 1 |
|
| March 13, 2020 |
8-K 1 gnbt031320form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jur |
|
| March 2, 2020 |
Generex Signs Contract with Chinese Partners Beijing Zhonghua Investment Fund Management Co. |
|
| March 2, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2020 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Comm |
|
| March 2, 2020 | ||
| February 18, 2020 |
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 25, 2019 (the “Execution Date”), is entered into by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”). |
|
| February 18, 2020 |
EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 6, 2019 (the “Execution Date”), by and between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”). |
|
| February 18, 2020 |
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of August 14, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the “Buyer”). |
|
| February 18, 2020 |
PURCHASE AGREEMENT This Purchase Agreement (“Agreement”) is made and entered into on December 9, 2019 (“Effective Date”), by and between Generex Biotechnology Corporation, a Delaware corporation (“Company”), and the investor whose name appears on the signature page hereto (“Investor”). |
|
| February 18, 2020 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 14, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the “Company”), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 545 Boylston Street, 2nd Floor, Boston, MA 02116 (the “Buyer”). |
|
| February 18, 2020 |
GNBT / Generex Biotechnology Corp. S-1 - Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on February 18, 2020 Registration No. |
|
| February 18, 2020 |
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| February 13, 2020 |
GNBT / Generex Biotechnology Corp. / Creek Mountain Partners, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GENEREX BIOTECHNOLOGY CORPORATION (Name of Issuer) Common stock, par value $.001 (Title of Class of Securities) 371485103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 28, 2020 |
AMENDMENT AGREEMENT This Amendment Agreement (this "Amendment") dated as of January 27, 2020, is between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation with a business address located at 10102 USA Today Way, Miramar, Florida, 33025 ("Generex") and GH Care, Inc. |
|
| January 28, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2020 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commi |
|
| January 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| December 16, 2019 |
GNBT / Generex Biotechnology Corp. 10-Q - Quarterly Report - FORM 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 0-25169 Generex Biotechnology Cor |
|
| December 12, 2019 |
GNBT / Generex Biotechnology Corp. S-1 - Registration Statement - FORM S-1 S-1 1 gnbt120619forms1.htm FORM S-1 As filed with the Securities and Exchange Commission on December 12, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 2834 98-0178636 (State or other j |
|
| December 12, 2019 |
Subsidiaries of the Registrant (incorporated by reference to S-1 filed December 12, 2019) Exhibit 21 Following is a list of the Company's subsidiaries, each of which, unless otherwise indicated, is wholly owned by the Company either directly or through another subsidiary. |
|
| November 29, 2019 |
GNBT / Generex Biotechnology Corp. / Creek Mountain Partners, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GENEREX BIOTECHNOLOGY CORPORATION (Name of Issuer) Common stock, par value $.001 (Title of Class of Securities) 371485103 (CUSIP Number) January 14, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| November 27, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Comm |
|
| November 27, 2019 |
STOCK PURCHASE AGREEMENT CONFIDENTIAL DRAFT: for discussion Purposes ONLY THIS STOCK PURCHASE AGREEMENT (this “Agreement”), made effective November 15, 2019 (“Effective Date”) is entered into by and between GH Care, Inc. |
|
| November 12, 2019 |
GNBT / Generex Biotechnology Corp. 10-K - Annual Report - FORM 10-K United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: July 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-29169 Generex Biotechnology Corporation |
|
| October 29, 2019 |
Exhibit 99.1 Generex Biotechnology Announces Extension to the Pay Date for the Previously Declared 1:1 Stock Dividend - New Dates Established for 1:1 Shareholder stock dividend o Pay Date: November 29, 2019 o Ex-Date: December 2, 2019 o Record Date remains August 30, 2019 MIRAMAR, FL, October 29, 2019/ - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced t |
|
| October 29, 2019 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commi |
|
| October 29, 2019 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commiss |
|
| October 29, 2019 |
Exhibit 99.1 Generex Biotechnology Announces Extension to the Pay Date for the Previously Declared 1:1 Stock Dividend - New Dates Established for 1:1 Shareholder stock dividend o Pay Date: November 29, 2019 o Ex-Date: December 2, 2019 o Record Date remains August 30, 2019 MIRAMAR, FL, October 29, 2019/ - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced t |
|
| October 29, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Monday, October 25, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation |
|
| October 29, 2019 |
GNBT / Generex Biotechnology Corp. NT 10-K - - GENEREX BIOTECHNOLOGY CORPORATION FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ÖForm 10-K ¨ Form 20-F ¨ Form 11-K X Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: July 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q |
|
| October 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Monday, October 28, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporati |
|
| September 24, 2019 |
GNBT / Generex Biotechnology Corp. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A (Rule 14a-101) Schedule 14A Information Proxy Statement pursuant to §14(a) of The Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a party other than the registrant: ☐ Check the appropriate box: ☐ preliminary proxy statement confidential, for use of the commission only (as permitted by rule 14 a |
|
| July 16, 2019 |
ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is dated July 11, 2019 (the “Execution Date”), by and between (i) Medisource Partners, LLC, a Texas limited liability company (the “Seller”), and (ii) Generex Biotechnology Corporation, a Delaware corporation (“Parent”) and NuGenerex Distribution Solutions, LLC, a Delaware limited liability company (collectively, the “Buyer”). |
|
| July 16, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 11 July, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commissi |
|
| July 16, 2019 |
EX-10.2 3 ex102.htm EXHIBIT 10.2 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is dated July 11, 2019 (the “Execution Date”), by and between (i) Pantheon Medical - Foot & Ankle, LLC, a Delaware limited liability company (the “Seller”), and (ii) Generex Biotechnology Corporation, a Delaware corporation (“Parent”) and NuGenerex Distribution Solutions, LLC, a Delaware limi |
|
| June 19, 2019 |
GNBT / Generex Biotechnology Corp. 10-Q - Quarterly Report - FORM 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: 30 April 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 0-25169 Generex Biotechnology Corpor |
|
| June 17, 2019 |
GNBT / Generex Biotechnology Corp. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: April 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10- |
|
| June 5, 2019 |
Unaudited pro forma condensed combined financial information Exhibit 99.3 Unaudited pro forma condensed combined financial information The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the acquisition of substantially all the assets primarily used in ancillary health care service providers, primarily pharmacies, laboratories and investments in and management of managed service organizati |
|
| June 5, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Amendment No. 2 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2018 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorp |
|
| June 5, 2019 |
The accompanying notes are an integral part of these consolidated financial statements. Veneto Holdings, LLC Consolidated Financial Statements as of September 30, 2018 and December 31, 2017 and for the Nine Months Ended September 30, 2018 and the Year Ended December 31, 2017, and Report of Independent Auditor 1 VENETO HOLDINGS, LLC TABLE OF CONTENTS REPORT OF INDEPENDENT AUDITOR 3 CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2018 AND DECEMBER 31, 2017 AND FOR THE NINE MONTHS |
|
| June 5, 2019 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation Commission F |
|
| June 5, 2019 |
June 5, 2019 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street NE Washington, DC 20549 Dear Sir/Madam: We have read the statements under item 4.01 in the Form 8-K dated June 5, 2019 of Generex Biotechnology Corporation (the “Company”) to be filed with the U.S. Securities and Exchange Commission and we agree with such statements therein as related to our firm. We h |
|
| April 25, 2019 |
GNBT / Generex Biotechnology Corp. CORRESP - - Gary A. Miller 215.851.8472 [email protected] April 25, 2019 Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 S Street, NE Washington, DC 20549-0213 Attn: Keira Nakada Attn: Sharon Blume Re: Generex Biotechnology Corp. Form 10-K for the Fiscal Year Ended July 31, 2018 Filed October 26, 2018 Form 8-K/A Dated October 3, 2018 Filed Decemb |
|
| April 18, 2019 |
GNBT / Generex Biotechnology Corp. CORRESP - - Friday, 12 April 2019 Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 S Street, NE Washington, DC 20549-0213 ℅ Keira Nakada (202) 551-3659 nakadak@sec. |
|
| April 16, 2019 |
GNBT / Generex Biotechnology Corp. FORM 10-Q/A (Quarterly Report) United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: 31 January 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 000-29169 Generex |
|
| April 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Monday, 1 April 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporatio |
|
| April 4, 2019 |
RESTRUCTURING AGREEMENT This RESTRUCTURING AGREEMENT, dated March 28, 2019 (“Restructuring Agreement”), is made among Generex Biotechnology Corporation (the “Company” or “Generex”), NuGenerex Distribution Solutions 2, LLC, (the “Borrower”), Veneto Holdings, L. |
|
| April 4, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 gnbt040419form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Monday, 29 March 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State |
|
| March 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Monday, 25 March 2019 Generex biotechnology corpORATION (Exact of registrant as specified in its charter) DELAWARE 000-29169 98-0178636 State or other jurisdiction of incorporation |
|
| March 25, 2019 |
Regentys Corporation Financial Statements As of and for the Years Ended December 31, 2017 and 2016 Financial Statements As of and for the Years Ended December 31, 2017 and 2016 1 Regentys Corporation Financial Statements As of and for the Years Ended December 31, 2017 and 2016 2 Regentys Corporation Contents Page Independent Auditor’s Report 4 - 5 Financial Statements Balance Sheets 6 Statements of Operations 7 Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit 8 Sta |
|
| March 25, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment # 1 to Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction |
|
| March 25, 2019 |
Condensed Financial Statements As of September 30, 2018 and December 31, 2017 and for the Nine Months Ended September 30, 2018 and 2017 1 Regentys Corporation Condensed Financial Statements As of September 30, 2018 and December 31, 2017 and for the Nine Months Ended September 30, 2018 and 2017 2 Regentys Corporation Contents Page Condensed Financial Statements (unaudited) Condensed Balance Sheets |
|
| March 25, 2019 |
Unaudited pro forma condensed combined financial information Exhibit 99.3 Unaudited pro forma condensed combined financial information On January 7, 2019, Regentys Corporation (“Regentys”) and Generex Biotechnology Corporation (“Generex” or the “Company”) completed closing of the stock purchase agreement (the “Stock Purchase Agreement”) previously announced in a binding letter of intent (“LOI”) on November 28, 2018 wherein the Company purchased 51% of the c |
|
| March 25, 2019 |
GNBT / Generex Biotechnology Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-25169 GENEREX BIOTECHNOLOGY |
|
| March 22, 2019 |
Financial Statements and Exhibits 8-K/A 1 gnbt031219form8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment # 1 to Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-2916 |
|
| March 22, 2019 |
Unaudited pro forma condensed combined financial information Exhibit 99.3 Unaudited pro forma condensed combined financial information On January 7, 2019, Olaregen Therapeutix Inc. ("Olaregen") and Generex Biotechnology Corporation (“Generex” or the “Company”) completed closing of the stock purchase agreement (the “Stock Purchase Agreement”) previously announced in a binding letter of intent (“LOI”) on November 28, 2018 wherein the Company purchased 51% of |
|
| March 22, 2019 |
Financial Statements OLAREGEN THERAPEUTIX INC. Period from inception (April 24, 2018) to June 30, 2018 Report of Independent Registered Public Accounting Firm 1 OLAREGEN THERAPEUTIX INC Table of Content Report of Independent Registered Public Accounting Firm 3 Financial Statements Balance Sheet as of June 30, 2018 4 Statement of Operations for the period from inception (April 24,2018) to June 30, |
|
| March 22, 2019 |
Financial Statements OLAREGEN THERAPEUTIX, INC. For the three months ended September 30, 2018 EX-99.2 4 ex992.htm EXHIBIT 99.2 Financial Statements OLAREGEN THERAPEUTIX, INC. For the three months ended September 30, 2018 (Unaudited) 1 Financial Statements (Unaudited) Balance Sheets – September 30, 2018 and June 30, 2018 3 Statement of Operations – For the three months ended September 30, 2018 and 2017 4 Statement of Changes in Stockholders’ Equity – September 30, 2018 5 Statement of Cash F |
|
| March 18, 2019 |
GNBT / Generex Biotechnology Corp. FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: January 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 1 |
|
| March 18, 2019 |
GNBT / Generex Biotechnology Corp. CORRESP - - Gary A. Miller 215.851.8472 [email protected] March 15, 2019 Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 S Street, NE Washington, DC 20549-0213 ℅ Keira Nakada (202) 551-3659 ℅ Sharon Blume (202) 551-3474 Re: Generex Biotechnology Corp. Form 10-K for the Fiscal Year Ended July 31, 2018 Filed October 26, 2018 Form 8-K/A Dated Octobe |
|
| March 18, 2019 |
GNBT / Generex Biotechnology Corp. CORRESP - - Deloitte Deloitte & Touche LLP JPMorgan Chase Tower 2200 Ross Avenue Suite 1600 Dallas, TX 75201-6778 USA Tel: +1 214 840 7000 www. |
|
| March 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| February 22, 2019 |
COMMON STOCK PURCHASE WARRANT GENEREX BIOTECHNOLOGY CORPORATION EX-4.3 4 ex43.htm EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT T |
|
| February 22, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 28, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the “Buyer”). |
|
| February 22, 2019 |
AMENDMENT #1 TO THE SECURITIES PURCHASE AGREEMENT, CONVERTIBLE PROMISSORY NOTE, AND COMMON STOCK PURCHASE WARRANT DATED JANUARY 28, 2019 THIS AMENDMENT #1 (the “Amendment”) to the SPA (as defined below), Note (as defined below), and Warrant (as defined below) is made effective as of February 13, 2019, by and between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “Holder”) (collectively the “Parties”). |
|
| February 22, 2019 |
THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE. |
|
| February 22, 2019 |
8-K 1 gnbt022219form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or |
|
| February 14, 2019 |
COMMON STOCK PURCHASE WARRANT GENEREX BIOTECHNOLOGY CORPORATION NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| February 14, 2019 |
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 4, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and LABRYS FUND, LP, a Delaware limited partnership (together with it permitted assigns, the “Buyer”). |
|
| February 14, 2019 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 14, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 4, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the “Company”), and LABRYS FUND, LP, a Delaware limited partnership, with its address at 48 Parker Road, Wellesley, MA 02482 (the “Buyer”). |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| February 13, 2019 |
Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| January 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| January 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| January 22, 2019 |
AMENDMENT AGREEMENT AMENDMENT AGREEMENT, dated as of January 15, 2019 (this “Agreement”), among Generex Biotechnology Corporation (the “Company” or “Generex”), NuGenerex Distribution Solutions 2, LLC, (the “Borrower”), Veneto Holdings, L. |
|
| January 22, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| January 11, 2019 |
PLEDGE AND SECURITY AGREEMENT CONFIDENTIAL DRAFT: FOR DISCUSSION PURPOSES ONLY THIS PLEDGE AND SECURITY AGREEMENT (the “Pledge”), is made and entered into this day of January 2019, (“Effective Date”) by and between GENEREX BIOTECHNOLOGY CORPORATION, A Delaware corporation ("Pledgor") and OLAREGEN THERAPEUTIX INC. |
|
| January 11, 2019 |
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED and RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of this day of January, 2019 by and among Olaregen Therapeutix Inc. |
|
| January 11, 2019 |
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), made effective January , 2019 (“Effective Date”), is entered into by and between OLAREGEN THERAPEUTIX INC. |
|
| January 11, 2019 |
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY OTHER APPLICABLE SECURITIES LAWS. |
|
| January 11, 2019 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) ( |
|
| January 11, 2019 |
MANAGEMENT SERVICES AGREEMENT This Management Services Agreement (the "Agreement") is entered into January , 2019 (the "Effective Date"), by and among REGENTYS CORPORATION, a Florida corporation with its principal place of business located at 6135 NW 167th Street, E-15, Miami Lakes, Florida (the "Corporation"), RICHARD C. |
|
| January 11, 2019 |
PLEDGE AND SECURITY AGREEMENT THIS PLEDGE AND SECURITY AGREEMENT (the “Pledge”), is made and entered into this January , 2019, (“Effective Date”) by and between GENEREX BIOTECHNOLOGY CORPORATION, A Delaware corporation ("Pledgor") and REGENTYS CORPORATION, A Florida corporation ("Pledgee"). |
|
| January 11, 2019 |
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY OTHER APPLICABLE SECURITIES LAWS. |
|
| January 11, 2019 |
AMENDED AND RESTATED SHAREHOLDERS AGREEMENT THIS AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (this “Agreement”) dated as of January , 2019 is entered into by and among REGENTYS CORPORATION, a Florida corporation (the “Corporation”), the investors named in the attached Schedule I and having an address as set forth therein (each an “Investor" and collectively the “Investors"), and the persons whose |
|
| January 11, 2019 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement 8-K 1 gnbt011119form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or ot |
|
| January 11, 2019 |
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), made effective January 7, 2019 (“Effective Date”) is entered into by and between REGENTYS CORPORATION, a Florida corporation (“Seller” or the “Corporation”) and GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, or an affiliate, (“Purchaser”). |
|
| December 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| December 24, 2018 |
GNBT / Generex Biotechnology Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2018 ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-25169 GENEREX BIOTECHNOLOGY |
|
| December 19, 2018 |
Unaudited pro forma condensed combined financial information Exhibit 99.3 Unaudited pro forma condensed combined financial information The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the acquisition of substantially all the assets primarily used in ancillary health care service providers, primarily pharmacies, laboratories and investments in and management of managed service organizati |
|
| December 19, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment # 1 to Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction |
|
| December 19, 2018 |
The accompanying notes are an integral part of these consolidated financial statements. Veneto Holdings, LLC Consolidated Financial Statements as of and for the Years Ended December 31, 2017 and 2016, and Report of Independent Auditors 1 VENETO HOLDINGS, LLC TABLE OF CONTENTS Page REPORT OF INDEPENDENT AUDITORS 3 CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2017 and 2016: Balance Sheets 4 Statements of Income 5 Statements of Changes in Equity 6 Stateme |
|
| December 19, 2018 |
Veneto Holdings, LLC Consolidated Financial Statements as of June 30, 2018 and December 31, 2017 and for the Six Months Ended June 30, 2018 and 2017 1 Veneto Holdings, LLC TABLE OF CONTENTS Page CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2018 AND DECEMBER 31, 2017 AND FOR THE SIX MONTHS ENDED JUNE 30, 2018 and 2017: Balance Sheets 3 Statements of Operations 4 Statements of Changes in Equity |
|
| December 17, 2018 |
GNBT / Generex Biotechnology Corp. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-25169 NOTIFICATION OF LATE FILING (Check One): ¨Form 10-K ¨ Form 20-F ¨ Form 11-K X Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: October 31, 2017 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10 |
|
| December 3, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| December 3, 2018 |
COVER SLIDE Moderator: Good morning and thank you for joining today’s conference call to discuss Generex Biotechnology’s corporate update. |
|
| December 3, 2018 |
Strictly Confidential December 3, 2018 Presenting Our New Vision As An Integrated Healthcare Holding Company 1 Legal Disclaimer 2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Forward - looking statements included in this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . |
|
| December 3, 2018 |
EX-4.1 2 ex41.htm EXHIBIT 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 26, 2018, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). WHE |
|
| December 3, 2018 |
STOCK PLEDGE AGREEMENT THIS STOCK PLEDGE AGREEMENT (this “Agreement”), dated as of November 26, 2018, by and between Joseph Moscato (“Pledgor”) and Istvan Elek (“Pledgee”); W I T N E S S E T H: WHEREAS, Pledgor is the President and Chief Executive officer of Generex Biotechnology Corporation (the “Company”); WHEREAS, the Company issued a Note to Pledgee in the principal amount of $1,060,000 dated |
|
| December 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| December 3, 2018 |
EX-4.2 3 ex42.htm EXHIBIT 4.2 Original Issue Date: November 26, 2018 Principal Amount: $1,060,000.00 Purchase Price: $1,000,000.00 NOTE DUE November 26, 2019 THIS NOTE is one of a series of duly authorized and validly issued Notes of Generex Biotechnology Corporation, a Delaware corporation, (the “Borrower”), having a place of business at 10102 USA Today Way, Miramar, Florida 33025, email: josephm |
|
| December 3, 2018 |
Generex Biotechnology Expands Medical Device Portfolio with Acquisition of Olaregen Therapeutix Inc. |
|
| December 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| December 3, 2018 |
EX-10.1 2 ex101.htm EXHIBIT 10.1 PRIVATE AND CONFIDENTIAL November 26, 2018 OLAREGEN THERAPEUTIX INC. 1001 Avenues of Americas New York, NY 10018 Attention: Anthony J. Dolisi, CEO & President Dear Sirs: Re: Binding Letter of Intent This letter agreement sets forth our agreement and understanding as to the essential terms of the sale to Generex Biotechnology Corporation (or an affiliate thereof) (t |
|
| December 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
|
| December 3, 2018 |
EX-10.1 2 ex101.htm EXHIBIT 10.1 AGREEMENT, ASSIGNMENT AND RELEASE This Agreement, Assignment and Release (this “Agreement’) is dated as of December 2nd, 2018, by and among STEPHEN L BERKMAN (“BERKMAN”), GENEREX BIOTECHNOLOGY CORPORATION (“GNBT”) and NUGENEREX DIAGNOSTICS, LLC formally known as HEMA DIAGNOSTIC SYSTEMS, LLC. (“HDS”). 1. GNBT is currently indebted to BERKMAN for advances made by Ber |
|
| December 3, 2018 |
EX-10.1 3 ex101.htm EXHIBIT 10.1 STOCK CONTROL AGREEMENT This STOCK CONTROL AGREEMENT (this “Agreement”) is made and entered into as of December 1, 2018 (the “Effective Date”) among Joseph Moscato, Lawrence Salvo, Stephen L. Berkman, and BH-Sanford, LLC (each a “Stockholder” and collectively the “Stockholders”) and Generex Biotechnology Corporation (the “Company”). BACKGROUND A. The Stockholders a |
|
| December 3, 2018 |
Form of Warrant To Purchase Common Stock Form of Warrant To Purchase Common Stock EXCEPT AS PROVIDED IN THE REGISTRATION STATEMENT OF THE COMPANY ON FORM S-4, THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR APPLICABLE STATE SECURITIES LAWS. |
|
| December 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2018 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-29169 98-0178636 (State or other jurisdiction of incorporation) |
